Roche Holding said its immunotherapy drug Tecentriq slowed the progression of lung cancer and helped patients live longer in a late-stage study, bolstering the Swiss drugmaker’s defense against a wave of cut-price competition to its top-selling medicines.

Sections:  world   
Topics:  europe   
RELATED ARTICLES
BING NEWS:
  • Targeted drug, radiotherapy could prolong lives of liver cancer patients with resistance to immunotherapy, Hong Kong studies find
    Chinese University researchers say patients in trial took oral targeted therapy once a day and underwent scans every six weeks After treatment, trial participants had median survival period of 14.3 ...
    04/4/2024 - 12:00 pm | View Link
  • Cancer Patients and Vaccines: Who and When to Vaccinate
    Patients should typically receive vaccines 2-4 weeks before cancer treatment, but non-live vaccines can be given during or after chemotherapy, immunotherapy, hormonal treatment, radiation, or surgery ...
    03/27/2024 - 11:15 pm | View Link
  • More

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More News